L
Lorraine A. Chantrill
Researcher at Wollongong Hospital
Publications - 67
Citations - 10491
Lorraine A. Chantrill is an academic researcher from Wollongong Hospital. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 22, co-authored 51 publications receiving 7940 citations. Previous affiliations of Lorraine A. Chantrill include Garvan Institute of Medical Research & University of New South Wales.
Papers
More filters
Proceedings ArticleDOI
Abstract CT210: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial
Lorraine A. Chantrill,Skye Simpson,Amber L. Johns,Mona Martyn-Smith,Angela Chou,Clare Watson,Adnan Nagrial,Venessa T. Chin,Lucille Sebastian,Sonia Yip,John Simes,Nick Pavlakis,Peter Grimison,Ray Asghari,Sandra Harvey,Andrew V. Biankin +15 more
TL;DR: The IMPaCT trial has recently been amended to a single arm pilot study of first line molecularly guided therapy for advanced pancreas cancer, and 2 of the 8 eligible cases have commenced precision therapy on trial.
Journal ArticleDOI
The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with “Quad WT”. J Clin Oncol 35 (15) 3572.
Eva Segelov,Jeremy Shapiro,Subotheni Thavaneswaran,Subotheni Thavaneswaran,Paul Waring,Jayesh Desai,Kirsty Mann,Maria Elena Elez,Lorraine A. Chantrill,Lorraine A. Chantrill,Lorraine A. Chantrill,Nick Pavlakis,Nick Pavlakis,Louise M. Nott,Craig Underhill,Mustafa Khasraw,Harpreet Wasan,Fortunato Ciardiello,Michael Jefford,Warren Joubert,Andrew Haydon,Christos Karapetis,Timothy J. Price,Kate Wilson +23 more
Journal ArticleDOI
European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions
Nick Pavlakis,Gary Tincknell,Lisi Elizabeth Lim,Kei Muro,Radka Obermannova,Sylvie Lorenzen,Yu Jo Chua,Christopher Jackson,Christos S. Karapetis,Timothy J. Price,Lorraine A. Chantrill,Eva Segelov,Florian Lordick +12 more
TL;DR: Positive evidence from key trials that have led to the current practice algorithm is highlighted, with particular focus on the refractory advanced disease setting, discussing the areas of active research and highlighting the factors, including biomarkers and the influence of ethnicity, that contribute to therapeutic decision-making.
Journal ArticleDOI
131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Andrew Dean,T. Price,Katrin Marie Sjoquist,Niranjan Aryal,J. Mumford,Fiona Day,Sonia Yip,Abbey Walsh,Derrick Ho Wai Siu,C. Gunderson Jackson,Shamsudheen Padinharakam,Matthew Burge,John C. Lynam,N. Tebbutt,Z. Wong,Lyn L. Lam,J W Lee,Lorraine A. Chantrill,Mack Harris +18 more
TL;DR: CEND-1 as mentioned in this paper is a cyclic tumor-penetrating peptide iRGD that may improve drug delivery by activating an endocytic/exocytic transport pathway by binding αvB3/5integrins and downstream neuropilin-1.